ESMO 23: Opdivo Matches Keytruda In Perioperative Lung Cancer

 
• By Elizabeth Cairns
  
Generate a summary of this article
Listen to this article
Beta

Bristol Myers Squibb’s PD-1 looks set to follow Merck & Co’s rival in a new lung cancer setting but might second place be the first loser?    

Group of surgeons doing surgery in hospital operating theater. Medical team doing critical operation. -

A success – and a pretty good one. New data on Opdivo revealed in a late-breaking abstract released early at this weekend’s European Society for Medical Oncology (ESMO) meeting in Madrid, suggests that Bristol Myers Squibb Company’s checkpoint inhibitor might be a serious rival to Merck & Co., Inc.’s powerhouse Keytruda.

Key Takeaways

  • Opdivo cuts the risk of progression, recurrence or death by 42% when used perioperatively for non-small cell lung cancer

The setting is perioperative non-small cell lung cancer (NSCLC), in which a drug, plus chemotherapy, is given both before and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

 
• By Xu Hu

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

Allarity Hopes To Breathe New Life Into Ixempra In Breast Cancer

The US precision medicine company hopes its drug response predictor technology will enhance responses to the chemotherapy Ixempra on the basis of promising data from a handful of breast cancer patients in a Phase II trial, marking a positive turn in its journey to date.  

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.